Medical Oncologist
CION Cancer Clinics
Why atezolizumab plus bevacizumab is usually the first choice | CION Cancer Clinics
Atezolizumab plus bevacizumab is usually offered first because, in a large trial, people with advanced liver cancer lived longer on average than with sorafenib, the old standard tablet. That result changed the guidelines. This page explains the reasoning, how first-line treatment changed over time, and the situations where a different first treatment is the safer or better choice. At CION Cancer Clinics, a multidisciplinary tumour board weighs your liver function and your scans before recommending any treatment.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Why do doctors usually start with atezolizumab plus bevacizumab?
- What made it the standard first option?
- How did first-line treatment change over time?
- When might a different first treatment be chosen?
- Who is it not the right first choice for?
- What this page cannot tell you
- Common questions about why it comes first
The short answer
Why do doctors usually start with atezolizumab plus bevacizumab?
Because in a large international trial, people with advanced liver cancer who received this pair lived longer on average, and kept a better quality of life for longer, than people who took sorafenib, the tablet that had been the standard for over a decade. Major guidelines changed after that result, and the combination became the usual first option.
Usually, not always
The word "usually" matters. The trial included people whose liver was still working well, who had not had a transplant, and whose bleeding risk had been checked. If you fit that picture, this is generally where the discussion starts. If you do not, another first option may be safer or better.
Which cancer this applies to
This is about hepatocellular carcinoma (HCC), cancer that begins in the liver cells. It does not apply to cancer that spread to the liver from another organ, or to bile duct cancer, which have their own first treatments. For the treatment itself, see atezolizumab plus bevacizumab for liver cancer.
The reasoning
What made it the standard first option?
No single reason settled it. Several points lined up together.
It beat the old standard head to head
Many new drugs are tested against nothing, or against a dummy. This pair was tested directly against sorafenib, and it came out ahead on the measure that matters most to families: how long people lived. It also delayed the point at which the cancer started growing again.
Tumours shrank more often
More people saw their tumours get smaller on scans. Shrinking does not happen for everyone, but when it does it can ease pain and pressure symptoms.
Daily life held up better
People in the trial reported that their quality of life and day to day functioning declined later than with sorafenib.
Side effects differ in kind
- Raised blood pressure and protein in the urine
- Immune inflammation of the thyroid, liver or bowel
- Fewer of the hand-foot skin problems tablets bring
The two drugs help each other
Bevacizumab appears to make the tumour's surroundings less hostile to the immune system, which may help atezolizumab work. The mechanics are explained on the immunotherapy for liver cancer page.
Not sure whether this applies to you?
Ask an oncologistHow the standard moved
How did first-line treatment change over time?
-
Ordinary chemotherapy fell short
For a long time there was little to offer. Standard chemotherapy drugs did little for liver cancer and were hard on a damaged liver. See why ordinary chemotherapy barely works.
-
Sorafenib became the first standard
Sorafenib was the first tablet to show people lived longer with advanced HCC. It remained the main option for years, and it is still used today.
-
Lenvatinib matched it
A later trial found lenvatinib was at least as good as sorafenib, giving doctors a second tablet to choose from.
-
Atezolizumab plus bevacizumab moved ahead
This was the first combination to beat sorafenib on survival, and guidelines placed it first for suitable patients.
-
Durvalumab plus tremelimumab joined it
Another immunotherapy pair also beat sorafenib, and it does not carry the bevacizumab bleeding concern. Guidelines now list both. Read about durvalumab plus tremelimumab.
When the first choice changes
When might a different first treatment be chosen?
Your situation
What is often considered instead
High bleeding risk or recent variceal bleed
Durvalumab plus tremelimumab, or a tablet
A past liver transplant
Usually a tablet such as sorafenib or lenvatinib
Active autoimmune disease
Usually a tablet
Weaker liver function, Child-Pugh B
Case by case; sometimes a tablet or comfort-focused care
Cannot travel often for drips
Tablets at home may be easier; discuss it openly
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Did you know
Most people in the main trial had liver cancer linked to hepatitis B or C, which is the pattern seen in many families in India. People with hepatitis B took part once the virus was controlled with antiviral tablets.
Not for everyone
Who is it not the right first choice for?
A guideline describes the average patient in a trial. You may not be that patient. The pair is usually not the first choice if you have had a liver transplant, if your varices have bled recently or have not been treated, if you have an active autoimmune illness, or if your liver is failing, with deep yellowing, confusion or fluid that keeps coming back.
When local treatment still fits
If the cancer is small or limited to part of the liver, surgery, ablation or TACE may still be the right first step, and a drug that travels through the whole body may not be needed yet. See when tablets or infusions become the main treatment.
When comfort comes first
For some people the most helpful plan is care focused on symptoms and comfort. Choosing that is a medical decision, made with your family, and it is never giving up on the person.
Being straight with you
What this page cannot tell you
It cannot tell you whether this combination will work for you. A trial result describes a large group on average. Within that group some people did very well and some did not benefit, and nobody can tell in advance which group one person will fall into.
It cannot weigh your own risks
Your bleeding risk, your heart, your liver tests and your daily strength change the balance. Only a team that has seen your reports can put them together.
Who can answer it
A medical oncologist, working with a hepatologist, after your case has been discussed at a tumour board. If you were told this is your first treatment and want to understand why, ask your doctor to explain which of the reasons on this page apply to you.
Questions we are asked
Common questions about why it comes first
Is sorafenib now outdated?
No. Sorafenib and lenvatinib are still used, both as first treatment for people who cannot have immunotherapy and later, after immunotherapy stops working. They are tablets taken at home, which some families find easier. Read how that choice is made today.
Does first choice mean it is the strongest treatment?
It means it had the strongest evidence for a particular group of patients when compared with the old standard. It does not mean it suits everyone, or that it will work better than the alternatives for you. The right first choice depends on your liver, your bleeding risk and your health.
Is it better than durvalumab plus tremelimumab?
The two pairs have never been compared directly in a trial. Both beat sorafenib, and guidelines list both as first options. The choice often comes down to bleeding risk, the number of hospital visits, and what is available and covered. Your oncologist will explain which fits your case.
Was the evidence tested on Indian patients?
The main trial ran across many countries and included a large share of Asian patients, most with hepatitis B. It was not an Indian trial. Doctors apply its results here because the disease pattern is similar, while staying alert to local differences.
Can a cancer at an earlier stage be treated with it?
It is meant for cancer that cannot be removed or treated locally. Using it around surgery or ablation for early cancer is still being studied, and it is not a routine choice at that stage. If local treatment is possible, that usually comes first.
What if I cannot afford it?
Tell your team early. Biosimilar bevacizumab can lower part of the bill, and scheme or insurance cover may help. A tablet may be a reasonable alternative in some cases. CION can help with scheme paperwork and a written estimate. See the monthly cost of each option.
Will I still need hepatitis B tablets?
If you carry hepatitis B, yes. The antiviral tablets keep the virus controlled so it does not flare during treatment. Hepatitis B is controlled, not removed. Never stop these tablets without speaking to the doctor who prescribed them.
Can CION check whether I am suitable?
Yes. A CION medical oncologist can review your scans, blood reports and endoscopy findings, and the tumour board can discuss the case. Any missing scans or an endoscopy are arranged through partner hospitals. Call the helpline to find out which reports to bring.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Immunotherapy for Liver Cancer
- EASL — EASL Clinical Practice Guidelines: management of hepatocellular carcinoma
- American Cancer Society — Treatment of Liver Cancer, by Stage
- Cancer Research UK — Treatment for liver cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Atezolizumab plus bevacizumab for liver cancerWhat the treatment involves, step by stepWho cannot have atezolizumab plus bevacizumabThe reasons it may be ruled out for youChoosing between immunotherapy and tabletsHow the two routes are weighed against each otherDurvalumab plus tremelimumab for liver cancerThe other first-line immunotherapy pair
Talk to us
Want to know whether this first choice fits you?
Send us your scans, blood reports and endoscopy findings, and a medical oncologist will explain which first option suits your liver and your health. One helpline serves every CION centre.